J.P. Marvel Investment Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

J.P. Marvel Investment Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-63,771	Closed	-$8.41M	–	70
2025 Q1	$8.41M	Sell	63,771 -475	-0.7%	-$59.2K	1.46%	23
2024 Q4	$5.37M	Sell	64,246 -585	-0.9%	-$48.1K	0.89%	30
2024 Q3	$4.74M	Sell	64,831 -50	-0.1%	-$3.76K	0.77%	36
2024 Q2	$4.44M	Sell	64,881 -5	-0%	-$347	0.73%	34
2024 Q1	$4.49M	Hold	64,886	–	–	0.78%	38
2023 Q4	$4.65M	Sell	64,886 -270	-0.4%	-$15.5K	0.92%	30
2023 Q3	$3.39M	Hold	65,156	–	–	0.73%	36
2023 Q2	$4.13M	Sell	65,156 -330	-0.5%	-$20.6K	0.86%	33
2023 Q1	$3.55M	Buy	65,486 +670	+1%	+$32.4K	0.8%	36
2022 Q4	$3.43M	Sell	64,816 -37	-0.1%	-$1.85K	0.8%	36
2022 Q3	$3.02M	Sell	64,853 -5	-0%	-$261	0.77%	36
2022 Q2	$3.7M	Hold	64,858	–	–	0.89%	36
2022 Q1	$3.97M	Buy	+64,858	New	+$3.37M	0.81%	36

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

J.P. Marvel Investment Advisors's ITCI Position: Q2 2025 in Review

J.P. Marvel Investment Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 63,771 shares — an estimated $8.41M sold.

J.P. Marvel Investment Advisors first reported a position in ITCI in Q1 2022 and held it in 13 quarters. The position peaked at $8.41M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

J.P. Marvel Investment Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
J.P. Marvel Investment Advisors sold 63,771 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $8.41M.
J.P. Marvel Investment Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 13 quarters.
J.P. Marvel Investment Advisors's Intra-Cellular Therapies Inc. position peaked at $8.41M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on J.P. Marvel Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.